Lipocine (NASDAQ:LPCN) Upgraded at StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research note issued to investors on Monday.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective for the company.

Lipocine Price Performance

Shares of LPCN opened at $5.08 on Monday. The business has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $5.59. Lipocine has a 52 week low of $2.31 and a 52 week high of $11.79. The stock has a market cap of $27.17 million, a price-to-earnings ratio of -2.97 and a beta of 1.22.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million during the quarter. On average, equities analysts anticipate that Lipocine will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC increased its holdings in Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.